Resignation of Chief Executive Officer

27 September 2019
NZX Announcement

RESIGNATION OF CHIEF EXECUTIVE OFFICER
TruScreen advises that Mr Martin Dillon has resigned as the Chief Executive Officer of
the Company and will leave on completion of his notice period in late December 2019.
Martin has been with Truscreen since January 2014 and has been a key member of the
TruScreen executive team which was responsible for driving further development of the
TruScreen device, overseeing the successful growth of our major distributors in China,
Vietnam and Mexico and developing new markets, including India, Zimbabwe and Russia.
Martin will continue his association with Truscreen as a consultant post resignation.
The Company will commence a recruitment process for a replacement Chief Executive
to lead the Company forward into its next phase of its development.
Tony Ho, Chairman commented, “On behalf of the Board I would like to thank Martin for
his significant contribution to the growth and development of TruScreen over the last 5
years. We wish him well as he returns to his previous successful marketing career in
Sports management.”

Anthony Ho
Chairman

For more information visit www.TruScreen.com or contact:

TruScreen
Anthony Ho
Chairman
tonyho@truscreen.com

TruScreen
Guy Robertson
CFO
guyrobertson@truscreen.com
Investors
Investor Relations
Phone: +61 2 9237 2801
TruScreen@we-buchan.com

About TruScreen:
Watch our video on TruScreen: http://truscreen.com/truscreen-the-company/truscreen-
ultra-video/
TruScreen is a Cervical Cancer Screening Device
which offers the latest technology in cervical
screening, providing real-time, accurate detection
of pre-cancerous and cancerous cervical cells to
help improve the health and well-being of women
around the world. TruScreen’s real-time cervical cancer
technology utilises a digital wand which is placed on the surface
of the cervix to measure electrical and optical signals from the
surrounding tissues. A sophisticated proprietary algorithm
framework is utilised to detect pre-cancerous change, or cervical
intraepithelial neoplasia (CIN), by optical and electrical measurement of cervical tissue.
TruScreen offers an alternative approach to cervical screening, resolving many of the
ongoing issues with Pap tests including failed samples, poor patient follow up, patient
discomfort and the need for supporting laboratory infrastructures. As such, TruScreen
target market is developing countries where no large scale cervical cancer screening
programs and infrastructure are in place, such as; China, Mexico, Africa, Russia and India.
TruScreen’s cervical cancer screening device is EC certified for use throughout Europe and
CFDA approved for sale in China. Truscreen gained recognition from Global NGO’s WHO and
Unitaid in a joint Cervical Cancer Technology Landscape released at the 72
nd
World Health
Assembly.
For more information, visit our website at www.truscreen.com